<div id="readability-page-1"><p>Piper Sandler analyst Allison Bratzel maintained a Buy rating on Ultragenyx Pharmaceutical today and set a price target of $68.00.</p><h3>Claim 55% Off TipRanks</h3><ul><li>Unlock  hedge fund-level data  and  powerful investing tools  for smarter, sharper decisions  </li><li> Discover top-performing stock ideas and upgrade to a portfolio of market leaders with  Smart Investor Picks  </li></ul> <p>Bratzel covers the Healthcare sector, focusing on stocks such as Cogent Biosciences, Ardelyx, and Travere Therapeutics. According to TipRanks, Bratzel has an average return of <span>45.1%</span> and a 62.66% success rate on recommended stocks. </p> <p>Currently, the analyst consensus on Ultragenyx Pharmaceutical is a Strong Buy with an average price target of $52.56.</p></div>

RARE

ARKG

<p>Piper Sandler analyst Allison Bratzel has maintained a Buy rating on Ultragenyx Pharmaceutical (RARE) with a price target of $68.00. The analyst consensus for the company is a Strong Buy, with an average price target of $52.56. Bratzel has an average return of 45.1% and a 62.66% success rate on her stock recommendations, focusing on the Healthcare sector.</p>

Tip Ranks

Ultragenyx Pharma

iShares Global Healthcare

Ark Genomic Revolution ETF

First Trust NYSE Arca Biotech Index Fd

VanEck Biotech ETF

ALPS Medical Breakthrough

iShares US Pharma

VG Health

Invesco Nasdaq Biotechnology ETF

iShares Biotechnology ETF

Invesco Biotechnology & Genome ETF

Health Care Select Sector SPDR

SPDR S&P Biotech

Direxion S&P Biotech Bull 3X

Piper Sandler Cos

Cogent Biosciences

Ardelyx

Travere Therapeutics

Ultragenyx Pharmaceutical (RARE) Gets a Buy from Piper Sandler